Company news
Shield Therapeutics Plc (LSE:STX) news
Shield Therapeutics Plc news releases on 6ix. Latest, Jul 14, 2022: New Drug Submission accepted by Health Canada
Press releases — page 3
New Drug Submission accepted by Health Canada
July 14, 2022
Notice of General Meeting
July 8, 2022
2021 Annual Report and 2022 AGM Notice
June 30, 2022
KYE Pharmaceuticals Files Accrufer® NDS in Canada
March 21, 2022
Shield Therapeutics (STX) - PBMs have bought in...
March 2, 2022
Investor Presentation
February 25, 2022
KOL Investor Event on Iron Deficiency
February 4, 2022
Licence Agreement in Canada for Accrufer®
January 5, 2022
Patient Access Expands for Accrufer®
December 16, 2021
Shield Therapeutics (STX) Life Sciences Investo...
October 7, 2021
Jose A. Menoyo Appointed as Chief Medical Officer
September 27, 2021
Investor presentation
September 21, 2021
Shield Therapeutics (STX) - Focused on US marke...
August 20, 2021
Hardman & Co Video Event | Shield Therapeut...
August 12, 2021
AEGIS-CKD study results published in AJKD
August 9, 2021
US launch of Accrufer® confirmed for July 1, 2021
June 24, 2021
Directorate Change
June 18, 2021
Results of 2021 Annual General Meeting
June 17, 2021
Appointment of new Chief Executive Officer
May 28, 2021
Shield Therapeutics (STX): Accrufer launch on s...
May 26, 2021
US update
May 21, 2021
AEGIS-H2H study results published in IBD
May 18, 2021
Commencement of trading on the OTCQX Best Market
May 17, 2021
2020 Annual Report and 2021 AGM Notice
May 13, 2021
Appointment of Two Non-Executive Directors
May 10, 2021
Preliminary Results
April 29, 2021
Study demonstrates effectiveness of ferric maltol
March 26, 2021
Shield appoints new Chief Financial Officer
March 22, 2021
Australia's TGA approves Feraccru
March 9, 2021
PDMR/PCA Transaction Notification
March 4, 2021
Publication of Circular and Notice of GM
March 1, 2021
Successful completion of £25 million Fundraise
February 26, 2021
Shield Therapeutics (STX): Beefing up for the U...
February 2, 2021
Shareholder loan facilities
January 29, 2021
Director/PDMR Shareholding
January 21, 2021
Business and trading update
January 15, 2021
Shield Therapeutics (STX): Reassessing the US o...
January 6, 2021
PDMR Exercise of Share Options
December 18, 2020
Update re US partnering discussions
December 10, 2020
Withdrawal of all oppositions by TEVA
October 19, 2020
Shield Therapeutics (STX): Optimism over US deal
September 18, 2020
AEGIS-H2H study reanalysis
August 6, 2020
Total Voting Rights update
July 31, 2020
PT20 paper publication
July 16, 2020
Appointment of Non-Executive Director
June 26, 2020
Results of 2020 Annual General Meeting
June 18, 2020
Feraccru®/Accrufer® publications
June 3, 2020
Investor presentations
May 28, 2020
Appointment of Chairman
May 26, 2020
2019 Annual Report and 2020 AGM Notice
May 22, 2020